Global Pneumococcal 13-valent Conjugate Vaccine Market Growth 2026-2032
The global Pneumococcal 13-valent Conjugate Vaccine market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
The Pneumococcal 13-valent Conjugate Vaccine (PCV13) is a vaccine designed to protect against infections caused by Streptococcus pneumoniae bacteria, commonly known as pneumococcus. It targets 13 specific strains (or serotypes) of the bacteria, which are responsible for severe illnesses such as pneumonia, meningitis, and sepsis. By preventing these infections, PCV13 is particularly important in protecting young children, and people with weakened immune systems.
United States market for Pneumococcal 13-valent Conjugate Vaccine is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Pneumococcal 13-valent Conjugate Vaccine is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Pneumococcal 13-valent Conjugate Vaccine is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Pneumococcal 13-valent Conjugate Vaccine players cover Pfizer, Walvax, BIOKANGTAI, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Pneumococcal 13-valent Conjugate Vaccine Industry Forecast” looks at past sales and reviews total world Pneumococcal 13-valent Conjugate Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Pneumococcal 13-valent Conjugate Vaccine sales for 2026 through 2032. With Pneumococcal 13-valent Conjugate Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pneumococcal 13-valent Conjugate Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Pneumococcal 13-valent Conjugate Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pneumococcal 13-valent Conjugate Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Pneumococcal 13-valent Conjugate Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pneumococcal 13-valent Conjugate Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pneumococcal 13-valent Conjugate Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Pneumococcal 13-valent Conjugate Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Pneumococcal 13-valent Conjugate Vaccine market?
What factors are driving Pneumococcal 13-valent Conjugate Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Pneumococcal 13-valent Conjugate Vaccine market opportunities vary by end market size?
How does Pneumococcal 13-valent Conjugate Vaccine break out by Type, by Application?
The report requires updating with new data and is sent in 48 hours after order is placed.
The Pneumococcal 13-valent Conjugate Vaccine (PCV13) is a vaccine designed to protect against infections caused by Streptococcus pneumoniae bacteria, commonly known as pneumococcus. It targets 13 specific strains (or serotypes) of the bacteria, which are responsible for severe illnesses such as pneumonia, meningitis, and sepsis. By preventing these infections, PCV13 is particularly important in protecting young children, and people with weakened immune systems.
United States market for Pneumococcal 13-valent Conjugate Vaccine is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Pneumococcal 13-valent Conjugate Vaccine is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Pneumococcal 13-valent Conjugate Vaccine is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Pneumococcal 13-valent Conjugate Vaccine players cover Pfizer, Walvax, BIOKANGTAI, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Pneumococcal 13-valent Conjugate Vaccine Industry Forecast” looks at past sales and reviews total world Pneumococcal 13-valent Conjugate Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Pneumococcal 13-valent Conjugate Vaccine sales for 2026 through 2032. With Pneumococcal 13-valent Conjugate Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pneumococcal 13-valent Conjugate Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Pneumococcal 13-valent Conjugate Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pneumococcal 13-valent Conjugate Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Pneumococcal 13-valent Conjugate Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pneumococcal 13-valent Conjugate Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pneumococcal 13-valent Conjugate Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Pneumococcal 13-valent Conjugate Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- 0.5ml
- Other
- Hospital
- Clinic
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- Walvax
- BIOKANGTAI
What is the 10-year outlook for the global Pneumococcal 13-valent Conjugate Vaccine market?
What factors are driving Pneumococcal 13-valent Conjugate Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Pneumococcal 13-valent Conjugate Vaccine market opportunities vary by end market size?
How does Pneumococcal 13-valent Conjugate Vaccine break out by Type, by Application?
The report requires updating with new data and is sent in 48 hours after order is placed.
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Pneumococcal 13-valent Conjugate Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Pneumococcal 13-valent Conjugate Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Pneumococcal 13-valent Conjugate Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Pneumococcal 13-valent Conjugate Vaccine Segment by Type
2.2.1 0.5ml
2.2.2 Other
2.2.3 Pneumococcal 13-valent Conjugate Vaccine Sales by Type
2.2.3.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type (2021-2026)
2.2.3.2 Global Pneumococcal 13-valent Conjugate Vaccine Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Pneumococcal 13-valent Conjugate Vaccine Sale Price by Type (2021-2026)
2.3 Pneumococcal 13-valent Conjugate Vaccine Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Pneumococcal 13-valent Conjugate Vaccine Sales by Application
2.3.3.1 Global Pneumococcal 13-valent Conjugate Vaccine Sale Market Share by Application (2021-2026)
2.3.3.2 Global Pneumococcal 13-valent Conjugate Vaccine Revenue and Market Share by Application (2021-2026)
2.3.3.3 Global Pneumococcal 13-valent Conjugate Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Pneumococcal 13-valent Conjugate Vaccine Breakdown Data by Company
3.1.1 Global Pneumococcal 13-valent Conjugate Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Pneumococcal 13-valent Conjugate Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Company (2021-2026)
3.2.2 Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Pneumococcal 13-valent Conjugate Vaccine Sale Price by Company
3.4 Key Manufacturers Pneumococcal 13-valent Conjugate Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Pneumococcal 13-valent Conjugate Vaccine Product Location Distribution
3.4.2 Players Pneumococcal 13-valent Conjugate Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Pneumococcal 13-valent Conjugate Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Pneumococcal 13-valent Conjugate Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Pneumococcal 13-valent Conjugate Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Pneumococcal 13-valent Conjugate Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Pneumococcal 13-valent Conjugate Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Pneumococcal 13-valent Conjugate Vaccine Sales Growth
4.4 APAC Pneumococcal 13-valent Conjugate Vaccine Sales Growth
4.5 Europe Pneumococcal 13-valent Conjugate Vaccine Sales Growth
4.6 Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Growth
5 AMERICAS
5.1 Americas Pneumococcal 13-valent Conjugate Vaccine Sales by Country
5.1.1 Americas Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026)
5.1.2 Americas Pneumococcal 13-valent Conjugate Vaccine Revenue by Country (2021-2026)
5.2 Americas Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026)
5.3 Americas Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pneumococcal 13-valent Conjugate Vaccine Sales by Region
6.1.1 APAC Pneumococcal 13-valent Conjugate Vaccine Sales by Region (2021-2026)
6.1.2 APAC Pneumococcal 13-valent Conjugate Vaccine Revenue by Region (2021-2026)
6.2 APAC Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026)
6.3 APAC Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Pneumococcal 13-valent Conjugate Vaccine by Country
7.1.1 Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026)
7.1.2 Europe Pneumococcal 13-valent Conjugate Vaccine Revenue by Country (2021-2026)
7.2 Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026)
7.3 Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine by Country
8.1.1 Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Pneumococcal 13-valent Conjugate Vaccine
10.3 Manufacturing Process Analysis of Pneumococcal 13-valent Conjugate Vaccine
10.4 Industry Chain Structure of Pneumococcal 13-valent Conjugate Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Pneumococcal 13-valent Conjugate Vaccine Distributors
11.3 Pneumococcal 13-valent Conjugate Vaccine Customer
12 WORLD FORECAST REVIEW FOR PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE BY GEOGRAPHIC REGION
12.1 Global Pneumococcal 13-valent Conjugate Vaccine Market Size Forecast by Region
12.1.1 Global Pneumococcal 13-valent Conjugate Vaccine Forecast by Region (2027-2032)
12.1.2 Global Pneumococcal 13-valent Conjugate Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Pneumococcal 13-valent Conjugate Vaccine Forecast by Type (2027-2032)
12.7 Global Pneumococcal 13-valent Conjugate Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Pneumococcal 13-valent Conjugate Vaccine Product Portfolios and Specifications
13.1.3 Pfizer Pneumococcal 13-valent Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Walvax
13.2.1 Walvax Company Information
13.2.2 Walvax Pneumococcal 13-valent Conjugate Vaccine Product Portfolios and Specifications
13.2.3 Walvax Pneumococcal 13-valent Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Walvax Main Business Overview
13.2.5 Walvax Latest Developments
13.3 BIOKANGTAI
13.3.1 BIOKANGTAI Company Information
13.3.2 BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Product Portfolios and Specifications
13.3.3 BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 BIOKANGTAI Main Business Overview
13.3.5 BIOKANGTAI Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Pneumococcal 13-valent Conjugate Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Pneumococcal 13-valent Conjugate Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Pneumococcal 13-valent Conjugate Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Pneumococcal 13-valent Conjugate Vaccine Segment by Type
2.2.1 0.5ml
2.2.2 Other
2.2.3 Pneumococcal 13-valent Conjugate Vaccine Sales by Type
2.2.3.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type (2021-2026)
2.2.3.2 Global Pneumococcal 13-valent Conjugate Vaccine Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Pneumococcal 13-valent Conjugate Vaccine Sale Price by Type (2021-2026)
2.3 Pneumococcal 13-valent Conjugate Vaccine Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Pneumococcal 13-valent Conjugate Vaccine Sales by Application
2.3.3.1 Global Pneumococcal 13-valent Conjugate Vaccine Sale Market Share by Application (2021-2026)
2.3.3.2 Global Pneumococcal 13-valent Conjugate Vaccine Revenue and Market Share by Application (2021-2026)
2.3.3.3 Global Pneumococcal 13-valent Conjugate Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Pneumococcal 13-valent Conjugate Vaccine Breakdown Data by Company
3.1.1 Global Pneumococcal 13-valent Conjugate Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Pneumococcal 13-valent Conjugate Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Company (2021-2026)
3.2.2 Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Pneumococcal 13-valent Conjugate Vaccine Sale Price by Company
3.4 Key Manufacturers Pneumococcal 13-valent Conjugate Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Pneumococcal 13-valent Conjugate Vaccine Product Location Distribution
3.4.2 Players Pneumococcal 13-valent Conjugate Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Pneumococcal 13-valent Conjugate Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Pneumococcal 13-valent Conjugate Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Pneumococcal 13-valent Conjugate Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Pneumococcal 13-valent Conjugate Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Pneumococcal 13-valent Conjugate Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Pneumococcal 13-valent Conjugate Vaccine Sales Growth
4.4 APAC Pneumococcal 13-valent Conjugate Vaccine Sales Growth
4.5 Europe Pneumococcal 13-valent Conjugate Vaccine Sales Growth
4.6 Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Growth
5 AMERICAS
5.1 Americas Pneumococcal 13-valent Conjugate Vaccine Sales by Country
5.1.1 Americas Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026)
5.1.2 Americas Pneumococcal 13-valent Conjugate Vaccine Revenue by Country (2021-2026)
5.2 Americas Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026)
5.3 Americas Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pneumococcal 13-valent Conjugate Vaccine Sales by Region
6.1.1 APAC Pneumococcal 13-valent Conjugate Vaccine Sales by Region (2021-2026)
6.1.2 APAC Pneumococcal 13-valent Conjugate Vaccine Revenue by Region (2021-2026)
6.2 APAC Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026)
6.3 APAC Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Pneumococcal 13-valent Conjugate Vaccine by Country
7.1.1 Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026)
7.1.2 Europe Pneumococcal 13-valent Conjugate Vaccine Revenue by Country (2021-2026)
7.2 Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026)
7.3 Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine by Country
8.1.1 Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Pneumococcal 13-valent Conjugate Vaccine
10.3 Manufacturing Process Analysis of Pneumococcal 13-valent Conjugate Vaccine
10.4 Industry Chain Structure of Pneumococcal 13-valent Conjugate Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Pneumococcal 13-valent Conjugate Vaccine Distributors
11.3 Pneumococcal 13-valent Conjugate Vaccine Customer
12 WORLD FORECAST REVIEW FOR PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE BY GEOGRAPHIC REGION
12.1 Global Pneumococcal 13-valent Conjugate Vaccine Market Size Forecast by Region
12.1.1 Global Pneumococcal 13-valent Conjugate Vaccine Forecast by Region (2027-2032)
12.1.2 Global Pneumococcal 13-valent Conjugate Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Pneumococcal 13-valent Conjugate Vaccine Forecast by Type (2027-2032)
12.7 Global Pneumococcal 13-valent Conjugate Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Pneumococcal 13-valent Conjugate Vaccine Product Portfolios and Specifications
13.1.3 Pfizer Pneumococcal 13-valent Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Walvax
13.2.1 Walvax Company Information
13.2.2 Walvax Pneumococcal 13-valent Conjugate Vaccine Product Portfolios and Specifications
13.2.3 Walvax Pneumococcal 13-valent Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Walvax Main Business Overview
13.2.5 Walvax Latest Developments
13.3 BIOKANGTAI
13.3.1 BIOKANGTAI Company Information
13.3.2 BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Product Portfolios and Specifications
13.3.3 BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 BIOKANGTAI Main Business Overview
13.3.5 BIOKANGTAI Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Pneumococcal 13-valent Conjugate Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Pneumococcal 13-valent Conjugate Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 0.5ml
Table 4. Major Players of Other
Table 5. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units)
Table 6. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type (2021-2026)
Table 7. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2021-2026) & ($ million)
Table 8. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Type (2021-2026)
Table 9. Global Pneumococcal 13-valent Conjugate Vaccine Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Pneumococcal 13-valent Conjugate Vaccine Sale by Application (2021-2026) & (K Units)
Table 11. Global Pneumococcal 13-valent Conjugate Vaccine Sale Market Share by Application (2021-2026)
Table 12. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2021-2026) & ($ million)
Table 13. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Application (2021-2026)
Table 14. Global Pneumococcal 13-valent Conjugate Vaccine Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Company (2021-2026) & (K Units)
Table 16. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Company (2021-2026)
Table 17. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Company (2021-2026)
Table 19. Global Pneumococcal 13-valent Conjugate Vaccine Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Pneumococcal 13-valent Conjugate Vaccine Producing Area Distribution and Sales Area
Table 21. Players Pneumococcal 13-valent Conjugate Vaccine Products Offered
Table 22. Pneumococcal 13-valent Conjugate Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share Geographic Region (2021-2026)
Table 27. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country/Region (2021-2026)
Table 31. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026) & (K Units)
Table 34. Americas Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country (2021-2026)
Table 35. Americas Pneumococcal 13-valent Conjugate Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units)
Table 37. Americas Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (K Units)
Table 38. APAC Pneumococcal 13-valent Conjugate Vaccine Sales by Region (2021-2026) & (K Units)
Table 39. APAC Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Region (2021-2026)
Table 40. APAC Pneumococcal 13-valent Conjugate Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units)
Table 42. APAC Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (K Units)
Table 43. Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026) & (K Units)
Table 44. Europe Pneumococcal 13-valent Conjugate Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units)
Table 46. Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Pneumococcal 13-valent Conjugate Vaccine
Table 52. Key Market Challenges & Risks of Pneumococcal 13-valent Conjugate Vaccine
Table 53. Key Industry Trends of Pneumococcal 13-valent Conjugate Vaccine
Table 54. Pneumococcal 13-valent Conjugate Vaccine Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Pneumococcal 13-valent Conjugate Vaccine Distributors List
Table 57. Pneumococcal 13-valent Conjugate Vaccine Customer List
Table 58. Global Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Pneumococcal 13-valent Conjugate Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Pneumococcal 13-valent Conjugate Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Pneumococcal 13-valent Conjugate Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Pfizer Basic Information, Pneumococcal 13-valent Conjugate Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 73. Pfizer Pneumococcal 13-valent Conjugate Vaccine Product Portfolios and Specifications
Table 74. Pfizer Pneumococcal 13-valent Conjugate Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Pfizer Main Business
Table 76. Pfizer Latest Developments
Table 77. Walvax Basic Information, Pneumococcal 13-valent Conjugate Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 78. Walvax Pneumococcal 13-valent Conjugate Vaccine Product Portfolios and Specifications
Table 79. Walvax Pneumococcal 13-valent Conjugate Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Walvax Main Business
Table 81. Walvax Latest Developments
Table 82. BIOKANGTAI Basic Information, Pneumococcal 13-valent Conjugate Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 83. BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Product Portfolios and Specifications
Table 84. BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. BIOKANGTAI Main Business
Table 86. BIOKANGTAI Latest Developments
Table 1. Pneumococcal 13-valent Conjugate Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Pneumococcal 13-valent Conjugate Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 0.5ml
Table 4. Major Players of Other
Table 5. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units)
Table 6. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type (2021-2026)
Table 7. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2021-2026) & ($ million)
Table 8. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Type (2021-2026)
Table 9. Global Pneumococcal 13-valent Conjugate Vaccine Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Pneumococcal 13-valent Conjugate Vaccine Sale by Application (2021-2026) & (K Units)
Table 11. Global Pneumococcal 13-valent Conjugate Vaccine Sale Market Share by Application (2021-2026)
Table 12. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2021-2026) & ($ million)
Table 13. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Application (2021-2026)
Table 14. Global Pneumococcal 13-valent Conjugate Vaccine Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Company (2021-2026) & (K Units)
Table 16. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Company (2021-2026)
Table 17. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Company (2021-2026)
Table 19. Global Pneumococcal 13-valent Conjugate Vaccine Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Pneumococcal 13-valent Conjugate Vaccine Producing Area Distribution and Sales Area
Table 21. Players Pneumococcal 13-valent Conjugate Vaccine Products Offered
Table 22. Pneumococcal 13-valent Conjugate Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share Geographic Region (2021-2026)
Table 27. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country/Region (2021-2026)
Table 31. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026) & (K Units)
Table 34. Americas Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country (2021-2026)
Table 35. Americas Pneumococcal 13-valent Conjugate Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units)
Table 37. Americas Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (K Units)
Table 38. APAC Pneumococcal 13-valent Conjugate Vaccine Sales by Region (2021-2026) & (K Units)
Table 39. APAC Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Region (2021-2026)
Table 40. APAC Pneumococcal 13-valent Conjugate Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units)
Table 42. APAC Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (K Units)
Table 43. Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026) & (K Units)
Table 44. Europe Pneumococcal 13-valent Conjugate Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units)
Table 46. Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Pneumococcal 13-valent Conjugate Vaccine
Table 52. Key Market Challenges & Risks of Pneumococcal 13-valent Conjugate Vaccine
Table 53. Key Industry Trends of Pneumococcal 13-valent Conjugate Vaccine
Table 54. Pneumococcal 13-valent Conjugate Vaccine Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Pneumococcal 13-valent Conjugate Vaccine Distributors List
Table 57. Pneumococcal 13-valent Conjugate Vaccine Customer List
Table 58. Global Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Pneumococcal 13-valent Conjugate Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Pneumococcal 13-valent Conjugate Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Pneumococcal 13-valent Conjugate Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Pneumococcal 13-valent Conjugate Vaccine Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Pfizer Basic Information, Pneumococcal 13-valent Conjugate Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 73. Pfizer Pneumococcal 13-valent Conjugate Vaccine Product Portfolios and Specifications
Table 74. Pfizer Pneumococcal 13-valent Conjugate Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Pfizer Main Business
Table 76. Pfizer Latest Developments
Table 77. Walvax Basic Information, Pneumococcal 13-valent Conjugate Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 78. Walvax Pneumococcal 13-valent Conjugate Vaccine Product Portfolios and Specifications
Table 79. Walvax Pneumococcal 13-valent Conjugate Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Walvax Main Business
Table 81. Walvax Latest Developments
Table 82. BIOKANGTAI Basic Information, Pneumococcal 13-valent Conjugate Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 83. BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Product Portfolios and Specifications
Table 84. BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. BIOKANGTAI Main Business
Table 86. BIOKANGTAI Latest Developments
LIST OF FIGURES
Figure 1. Picture of Pneumococcal 13-valent Conjugate Vaccine
Figure 2. Pneumococcal 13-valent Conjugate Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Pneumococcal 13-valent Conjugate Vaccine Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Pneumococcal 13-valent Conjugate Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 0.5ml
Figure 12. Product Picture of Other
Figure 13. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type in 2026
Figure 14. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Type (2021-2026)
Figure 15. Pneumococcal 13-valent Conjugate Vaccine Consumed in Hospital
Figure 16. Global Pneumococcal 13-valent Conjugate Vaccine Market: Hospital (2021-2026) & (K Units)
Figure 17. Pneumococcal 13-valent Conjugate Vaccine Consumed in Clinic
Figure 18. Global Pneumococcal 13-valent Conjugate Vaccine Market: Clinic (2021-2026) & (K Units)
Figure 19. Global Pneumococcal 13-valent Conjugate Vaccine Sale Market Share by Application (2025)
Figure 20. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Application in 2026
Figure 21. Pneumococcal 13-valent Conjugate Vaccine Sales by Company in 2026 (K Units)
Figure 22. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Company in 2026
Figure 23. Pneumococcal 13-valent Conjugate Vaccine Revenue by Company in 2026 ($ millions)
Figure 24. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Company in 2026
Figure 25. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 26. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Geographic Region in 2026
Figure 27. Americas Pneumococcal 13-valent Conjugate Vaccine Sales 2021-2026 (K Units)
Figure 28. Americas Pneumococcal 13-valent Conjugate Vaccine Revenue 2021-2026 ($ millions)
Figure 29. APAC Pneumococcal 13-valent Conjugate Vaccine Sales 2021-2026 (K Units)
Figure 30. APAC Pneumococcal 13-valent Conjugate Vaccine Revenue 2021-2026 ($ millions)
Figure 31. Europe Pneumococcal 13-valent Conjugate Vaccine Sales 2021-2026 (K Units)
Figure 32. Europe Pneumococcal 13-valent Conjugate Vaccine Revenue 2021-2026 ($ millions)
Figure 33. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales 2021-2026 (K Units)
Figure 34. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Revenue 2021-2026 ($ millions)
Figure 35. Americas Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country in 2026
Figure 36. Americas Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Country (2021-2026)
Figure 37. Americas Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type (2021-2026)
Figure 38. Americas Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Application (2021-2026)
Figure 39. United States Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 40. Canada Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 41. Mexico Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 42. Brazil Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 43. APAC Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Region in 2026
Figure 44. APAC Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Region (2021-2026)
Figure 45. APAC Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type (2021-2026)
Figure 46. APAC Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Application (2021-2026)
Figure 47. China Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 48. Japan Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 49. South Korea Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 50. Southeast Asia Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 51. India Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 52. Australia Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. China Taiwan Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country in 2026
Figure 55. Europe Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Country (2021-2026)
Figure 56. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type (2021-2026)
Figure 57. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Application (2021-2026)
Figure 58. Germany Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 59. France Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 60. UK Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 61. Italy Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 62. Russia Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country (2021-2026)
Figure 64. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type (2021-2026)
Figure 65. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Application (2021-2026)
Figure 66. Egypt Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. South Africa Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 68. Israel Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 69. Turkey Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 70. GCC Countries Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 71. Manufacturing Cost Structure Analysis of Pneumococcal 13-valent Conjugate Vaccine in 2026
Figure 72. Manufacturing Process Analysis of Pneumococcal 13-valent Conjugate Vaccine
Figure 73. Industry Chain Structure of Pneumococcal 13-valent Conjugate Vaccine
Figure 74. Channels of Distribution
Figure 75. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Forecast by Region (2027-2032)
Figure 76. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 77. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 78. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 79. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 80. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Pneumococcal 13-valent Conjugate Vaccine
Figure 2. Pneumococcal 13-valent Conjugate Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Pneumococcal 13-valent Conjugate Vaccine Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Pneumococcal 13-valent Conjugate Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 0.5ml
Figure 12. Product Picture of Other
Figure 13. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type in 2026
Figure 14. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Type (2021-2026)
Figure 15. Pneumococcal 13-valent Conjugate Vaccine Consumed in Hospital
Figure 16. Global Pneumococcal 13-valent Conjugate Vaccine Market: Hospital (2021-2026) & (K Units)
Figure 17. Pneumococcal 13-valent Conjugate Vaccine Consumed in Clinic
Figure 18. Global Pneumococcal 13-valent Conjugate Vaccine Market: Clinic (2021-2026) & (K Units)
Figure 19. Global Pneumococcal 13-valent Conjugate Vaccine Sale Market Share by Application (2025)
Figure 20. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Application in 2026
Figure 21. Pneumococcal 13-valent Conjugate Vaccine Sales by Company in 2026 (K Units)
Figure 22. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Company in 2026
Figure 23. Pneumococcal 13-valent Conjugate Vaccine Revenue by Company in 2026 ($ millions)
Figure 24. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Company in 2026
Figure 25. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 26. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Geographic Region in 2026
Figure 27. Americas Pneumococcal 13-valent Conjugate Vaccine Sales 2021-2026 (K Units)
Figure 28. Americas Pneumococcal 13-valent Conjugate Vaccine Revenue 2021-2026 ($ millions)
Figure 29. APAC Pneumococcal 13-valent Conjugate Vaccine Sales 2021-2026 (K Units)
Figure 30. APAC Pneumococcal 13-valent Conjugate Vaccine Revenue 2021-2026 ($ millions)
Figure 31. Europe Pneumococcal 13-valent Conjugate Vaccine Sales 2021-2026 (K Units)
Figure 32. Europe Pneumococcal 13-valent Conjugate Vaccine Revenue 2021-2026 ($ millions)
Figure 33. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales 2021-2026 (K Units)
Figure 34. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Revenue 2021-2026 ($ millions)
Figure 35. Americas Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country in 2026
Figure 36. Americas Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Country (2021-2026)
Figure 37. Americas Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type (2021-2026)
Figure 38. Americas Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Application (2021-2026)
Figure 39. United States Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 40. Canada Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 41. Mexico Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 42. Brazil Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 43. APAC Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Region in 2026
Figure 44. APAC Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Region (2021-2026)
Figure 45. APAC Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type (2021-2026)
Figure 46. APAC Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Application (2021-2026)
Figure 47. China Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 48. Japan Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 49. South Korea Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 50. Southeast Asia Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 51. India Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 52. Australia Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. China Taiwan Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country in 2026
Figure 55. Europe Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Country (2021-2026)
Figure 56. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type (2021-2026)
Figure 57. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Application (2021-2026)
Figure 58. Germany Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 59. France Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 60. UK Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 61. Italy Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 62. Russia Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country (2021-2026)
Figure 64. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type (2021-2026)
Figure 65. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Application (2021-2026)
Figure 66. Egypt Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. South Africa Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 68. Israel Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 69. Turkey Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 70. GCC Countries Pneumococcal 13-valent Conjugate Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 71. Manufacturing Cost Structure Analysis of Pneumococcal 13-valent Conjugate Vaccine in 2026
Figure 72. Manufacturing Process Analysis of Pneumococcal 13-valent Conjugate Vaccine
Figure 73. Industry Chain Structure of Pneumococcal 13-valent Conjugate Vaccine
Figure 74. Channels of Distribution
Figure 75. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Forecast by Region (2027-2032)
Figure 76. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 77. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 78. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 79. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 80. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share Forecast by Application (2027-2032)
